Protective effects of valsartan administration on doxorubicin‑induced myocardial injury in rats and the role of

Dong Cheng1, Libo Chen1, Wencheng Tu1

  • 1Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China.

Insights

Valsartan prevents doxorubicin-induced heart damage by reducing oxidative stress and downregulating myocardial NAD(P)H oxidase 2 and 4 expression in rats.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Doxorubicin (DOX) chemotherapy causes cardiotoxicity, limiting its clinical use.
  • Angiotensin receptor blockers may mitigate DOX-induced cardiomyopathy.
  • NAD(P)H oxidase (NOX) enzymes are implicated in DOX-induced oxidative stress.

Purpose of the Study:

  • To investigate if valsartan (Val) co-administration with DOX prevents myocardial injury.
  • To determine if valsartan modulates myocardial NAD(P)H oxidase (NOX) expression.
  • To assess the role of NOX2 and NOX4 in DOX-induced oxidative stress and apoptosis.

Main Methods:

  • Rats were divided into control, DOX, and DOX+Val groups for 10 weeks.
  • Echocardiography, and myocardial mRNA/protein expression of NOX1, NOX2, and NOX4 were analyzed.
  • In vitro studies used H9C2 cells to examine reactive oxygen species (ROS) and apoptosis under varying NOX2/NOX4 levels.

Main Results:

  • DOX+Val group showed improved cardiac function, reduced pathological lesions, and collagen volume fraction compared to the DOX group.
  • Myocardial NOX2 and NOX4 mRNA and protein expression were significantly downregulated in the DOX+Val group.
  • In vitro, NOX2/NOX4 knockdown reduced ROS and apoptosis in DOX-treated cells, while overexpression increased them.

Conclusions:

  • Valsartan co-administered with doxorubicin prevents DOX-induced myocardial injury in rats.
  • Valsartan mitigates DOX cardiotoxicity by reducing oxidative stress.
  • This protective effect is mediated by the downregulation of myocardial NOX2 and NOX4 expression.